Taken together, our work shows that targeting DDR1, BCR-ABL, or DDR1/BCR-ABL with EGFR-ERBB2 could offer a potential therapeutic strategy against WNT-activated (stem-like) and KRAS-mutant COAD, with translatable applications in stem-like refractory cancers such as GBMs. The gene discussed is KRAS; the disease is cancer.